ATE295724T1 - Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse - Google Patents

Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse

Info

Publication number
ATE295724T1
ATE295724T1 AT01948936T AT01948936T ATE295724T1 AT E295724 T1 ATE295724 T1 AT E295724T1 AT 01948936 T AT01948936 T AT 01948936T AT 01948936 T AT01948936 T AT 01948936T AT E295724 T1 ATE295724 T1 AT E295724T1
Authority
AT
Austria
Prior art keywords
waxest
cholesterylester
avasimibe
diseases
synthesis
Prior art date
Application number
AT01948936T
Other languages
English (en)
Inventor
Reynold Homan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE295724T1 publication Critical patent/ATE295724T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01948936T 2000-02-02 2001-01-23 Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse ATE295724T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17977800P 2000-02-02 2000-02-02
PCT/US2001/002190 WO2001056556A2 (en) 2000-02-02 2001-01-23 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders

Publications (1)

Publication Number Publication Date
ATE295724T1 true ATE295724T1 (de) 2005-06-15

Family

ID=22657957

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948936T ATE295724T1 (de) 2000-02-02 2001-01-23 Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse

Country Status (34)

Country Link
US (2) US6730703B2 (de)
EP (1) EP1263421B1 (de)
JP (1) JP2003531113A (de)
KR (1) KR20020073574A (de)
CN (1) CN1398182A (de)
AP (1) AP2002002612A0 (de)
AT (1) ATE295724T1 (de)
AU (1) AU781563B2 (de)
BG (1) BG107042A (de)
BR (1) BR0107954A (de)
CA (1) CA2398219A1 (de)
CR (1) CR6712A (de)
DE (1) DE60110897T2 (de)
DZ (1) DZ3288A1 (de)
EA (1) EA004255B1 (de)
EE (1) EE200200429A (de)
ES (1) ES2239145T3 (de)
GE (1) GEP20043286B (de)
HR (1) HRP20020717A2 (de)
HU (1) HUP0301010A3 (de)
IL (1) IL150865A0 (de)
IS (1) IS6478A (de)
MA (1) MA26872A1 (de)
MX (1) MXPA02007309A (de)
NO (1) NO20023659L (de)
NZ (1) NZ520330A (de)
OA (1) OA12173A (de)
PL (1) PL357041A1 (de)
PT (1) PT1263421E (de)
SK (1) SK10972002A3 (de)
UA (1) UA75345C2 (de)
WO (1) WO2001056556A2 (de)
YU (1) YU57502A (de)
ZA (1) ZA200206075B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281399A3 (de) * 2001-08-01 2004-02-11 Warner-Lambert Company Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
US20050031699A1 (en) 2003-06-26 2005-02-10 L'oreal Porous particles loaded with cosmetically or pharmaceutically active compounds
ES2313065T3 (es) 2003-10-09 2009-03-01 Warner-Lambert Company Llc Composiciones farmaceuticas que comprenden derivados de malonamida para disminuir la produccion de sebo.
BRPI0614028A2 (pt) 2005-02-24 2011-03-01 Warner Lambert Co inibidor cristalino de acat
FR2903999B1 (fr) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
FR2904002A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010087964A2 (en) 2009-01-28 2010-08-05 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
US4751026A (en) 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−(置換フエニルオキシ)−アルカン酸のアリ−ル−およびアラルキルアミド
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
IE61716B1 (en) 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
ATE61574T1 (de) 1987-07-02 1991-03-15 Warner Lambert Co N-((2,6-disubstituierte)-phenyl>-harnstoff und - carbamat-inhibitoren der acyl-coenzym a:cholesterol-acyltransferase.
US4948806A (en) 1988-03-30 1990-08-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5030653A (en) 1988-03-30 1991-07-09 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US4999373A (en) 1988-03-30 1991-03-12 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en) 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US4923896A (en) 1989-02-09 1990-05-08 Warner-Lambert Company N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US5155127A (en) 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
CA2022346A1 (en) 1989-08-04 1991-02-05 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
TW205037B (de) 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) 1990-01-22 1993-11-22 Mitsubishi Kasei Corp 1−フェニルアルキル−3−フェニル尿素誘導体
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DE69228069T2 (de) 1992-01-23 1999-05-20 Pfizer 4-Phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxochinolin Derivate, als antihypercholesterolemische und antiatherosklerotische Mittel
US6001860A (en) 1992-05-28 1999-12-14 Pfizer Inc. N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT)
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US5494172A (en) * 1994-05-12 1996-02-27 Miller Compressing Company Magnetic pulley assembly
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
WO1999067258A1 (en) * 1998-06-25 1999-12-29 Tularik Inc. Arylsulfonanilide phosphates
CA2423141A1 (en) * 2000-09-27 2002-04-04 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

Also Published As

Publication number Publication date
HUP0301010A2 (hu) 2003-08-28
US20040161393A1 (en) 2004-08-19
PL357041A1 (en) 2004-07-12
NO20023659D0 (no) 2002-08-01
AU781563B2 (en) 2005-06-02
MXPA02007309A (es) 2002-11-29
OA12173A (en) 2006-05-08
NO20023659L (no) 2002-09-25
US6730703B2 (en) 2004-05-04
US20030060507A1 (en) 2003-03-27
EE200200429A (et) 2003-12-15
SK10972002A3 (sk) 2003-07-01
AP2002002612A0 (en) 2002-09-30
CR6712A (es) 2004-01-14
KR20020073574A (ko) 2002-09-27
BG107042A (bg) 2003-04-30
WO2001056556A3 (en) 2002-03-07
ES2239145T3 (es) 2005-09-16
JP2003531113A (ja) 2003-10-21
UA75345C2 (en) 2006-04-17
GEP20043286B (en) 2004-07-26
YU57502A (sh) 2006-01-16
ZA200206075B (en) 2003-10-30
IS6478A (is) 2002-07-19
DE60110897T2 (de) 2006-03-23
DZ3288A1 (en) 2001-08-09
CN1398182A (zh) 2003-02-19
AU2971801A (en) 2001-08-14
EP1263421B1 (de) 2005-05-18
DE60110897D1 (de) 2005-06-23
BR0107954A (pt) 2002-10-22
MA26872A1 (fr) 2004-12-20
HUP0301010A3 (en) 2005-03-29
EA200200764A1 (ru) 2002-12-26
CA2398219A1 (en) 2001-08-09
EP1263421A2 (de) 2002-12-11
HRP20020717A2 (en) 2003-12-31
WO2001056556A2 (en) 2001-08-09
IL150865A0 (en) 2003-02-12
PT1263421E (pt) 2005-08-31
NZ520330A (en) 2004-02-27
EA004255B1 (ru) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ID30062A (id) Alanog-analog benzopiran tersubstitusi untuk pengobatan radang
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
ATE522218T1 (de) Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60103685D1 (de) Behandlung von Poriomania
DE60130691D1 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263421

Country of ref document: EP

REN Ceased due to non-payment of the annual fee